# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 pr...
CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024
HC Wainwright & Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and lowers the price...
CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate o...
Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosisNovel...
BTIG analyst Justin Zelin initiates coverage on CARISMA Therapeutics (NASDAQ:CARM) with a Buy rating and announces Price Tar...